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doi:10.1016/j.ejvs.2010.03.017Abstract Purpose: To assess primary success and safety of percutaneous transluminal angio-
plasty and/or stenting of innominate artery lesions and to compare its 30-day stroke/mortality
level with the literature data.
Methods: A total of 72 patients (77 stenoses, five recurrent, 58 symptomatic and 39 female)
with seven innominate vessel occlusions, nine subocclusive lesions and 61 significant (>60%)
stenoses of innominate artery treated between 2000 and 2009 were retrospectively reviewed.
With the exception of seven, all procedures were performed using a transfemoral approach. A
stent was implanted in 49 (63.6%) cases. Follow-up included neurological examination, carotid
duplex scan and office/telephone interview.
Results: Primary technical success was 93.5% (72/77). There was neither periprocedural (<48 h)
death, normajor neurological complication.Minor periprocedural neurological complications con-
sisted of 2/72 (2.6%) ipsilateral TIAs. Access site complications included 4 (5.2%) access site bleed-
ings. Follow-up was achieved in 65/72 (90.3%) of all patients and 68 (88.3%) of all procedures for
a mean of 42.3 months and revealed neither major neurological complication, nor additional TIA.
The cumulative primary patency rate was 100% at 12 months, 98 1.6% at 24 months, and 69.9
 8.5% at 96months. The cumulative secondary patency ratewas 100%at 12 and at 24months, and
81.5 7.7% at 96 months. Log-rank test showed no significant difference (pZ 0.79) in primary
cumulative patencies between PTA alone (nZ 28) or PTA/stent (nZ 49).
Conclusion: Transfemoral PTA with or without stent appears to be a safe treatment option for
innominate artery lesions.
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36 T.M. Paukovits et al.Before the era of endovascular approach, open surgery had The lesions were measured according to NASCET study.Table 1 Patient characteristics.
Total number of patients 72 (100)
Total number of interventions 77 (100)
Average age in years 56.56 (range 28e99)
Men 33 (45.8)
Stenosis 60e90% 61 (79.2)
Subocclusion 9 (11.7)
Occlusion 7 (9.1)
Comorbidity
Previous MI 25 (34.7)
Lower limb claudication 36 (50)
Hypertension 47 (65.3)
Hyperlipidaemia 30 (41.7)
Diabetes mellitus 13 (18.6)
Smoking 33 (45.8)
Preprocedural Symptoms
Hemisensory or motor deficit 16 (20.8)
Amaurosis 8 (10.4)
Upper limb claudication 40 (52)
Upper limb arterial
pressure asymmetry
8 (10.4)
Dizziness 28 (36.4)
Asymptomatic 19 (24.7)
Interventions
Successful intervention 72 (93.5)
PTA only 28 (36.4)
PTA and stent deployment 49 (63.6)
Values in parenthes indicate percentage.been the sole operative treatment for the stenotic and
occlusive supra-aortic trunk lesions.1 Although surgical
revascularisation results in long lasting patency, these
procedures are associated with high morbidity and
mortality rates.2e6 During the last two decades, balloon
angioplasty with or without stent deployment has become
an increasingly accepted treatment for stenotic and
occlusive supra-aortic arterial disease. Extrathoracic
bypasses and transpositions continue to be favoured by
surgeons, but they tend to be used for cases when endo-
vascular therapy failed. Data on endovascular treatment of
solely innominate artery lesions are scarce; most of these
studies focussed on the treatment of the combination of
several supra-aortic arteries simultaneously, and only
limited number of innominate artery lesions are evaluated,
mostly with short-time follow-up. Therefore, any conclu-
sions from these studies are limited. Natural history data
and treatment guidelines for carotid bifurcation stenting7e9
do not exist for innominate lesions. The aim of the current
study was to retrospectively evaluate the primary technical
and clinical success rate, safety and efficacy of the angio-
plasty (PTA) with or without stent placement in the treat-
ment of innominate artery lesions.
Patients and Methods
We present our experience on 72 consecutive patients who
underwent 77 angioplasty of the innominate artery. Our
retrospective cohort study has been carried out at a tertial
referral centre, between the 1 January 2000 and 31 February
2009. There were 39 women (54.2%) and 33 men (45.8%).
Patients had ameanageof 56.6 (range 28e82 years) (Table 1).
Intervention was performed when the patient had clinical
symptoms and/or clinically significant stenosis or occlusion of
the brachiocephalic vessel. Preprocedural symptoms con-
sistedof16 (20.8%)hemisensoryormotordeficit,eight (10.4%)
amaurosis fugax. 40 (52%) patients suffered of right-upper
limb claudication and 28 (36.4%) patients complained of
dizziness. There were 19 asymptomatic patients (24.7%)
whose angiographies were carried out under the suspicion of
stenoses on other supra-aortic arteries, revealing the lesions
in the innominate artery.
Concerning the patients’ co-morbidity, 25 patients
(34.7%) had previous myocardial infarction, 47 patients
(65.3%) had hypertension, 13 (18.6%) person suffered from
type II diabetes mellitus, 30 (41.7%) had hyperlipidaemia
(cholesterol >5.2 mmol l1), 36 patients (50%) had symp-
tomatic arterial occlusion in their lower extremities and 33
(45.8%) smoked (Table 1).
The initial diagnosis of innominate artery stenosis or
occlusion was based on the clinical data, pulse palpation of
the radial arteries and blood pressure measurement on
both arms. Preprocedural examination consisted of colour
duplex scan (CDS) of the extracranial arteries in all
patients. Post-stenotic flow pattern in the common carotis
artery (CCA) was considered indicative of a likely proximal
stenosis of the subclavian artery. Retrograde flow in the
right vertebral artery on duplex scan (14 patients; 18.2%)
defined subclavian steal syndrome. Stenoses and occlusions
were verified by preprocedural diagnostic angiography in all
cases, done in the same session with the treatment.There were seven innominate vessel occlusions (9.1%), nine
subocclusive lesions (11.7%) and 61 greater than 60%
stenoses (79.2%). Angiography revealed 13 (16.9%) simul-
taneous supra-aortic stenoses, which have been treated in
one stage with the innominate artery lesions. These con-
sisted of seven (9.1%) subclavian stenoses (five left, one
right, one bilateral), one (1.3%) left subclavian occlusion,
three (3.9%) ICA (two left, one right) stenoses and two
(2.6%) left CCA stenoses.
The patients have signed informed consent form. Before
the intervention, the patients were on 125 mg day1 aspirin
per os, in case of contraindication for aspirin, the patients
received 2 250 mg ticlopidin. During the procedure, 5000
U heparin i.v. was given. All procedures were performed in
the angiography suite with the patient under local anaes-
thesia. Diagnostic angioplasty was performed through
a femoral approach with a 4F sheath, which was replaced
with 7e8-F, 90-cm long introduction sheath in case of
intervention (Advanti plus; Cordis Johnson & Johnson,
Roden, the Netherlands) in all, but seven (9.1%) cases. In
seven cases brachial approach for intervention were gained
through 4e5-F introducer. Angle-tip guide wires (Terumo
guide wire; Terumo Medical, Tokyo, Japan) with a diameter
of 0.032 or 0.035 inch were used to pass the stenosis in the
brachiocephalic artery under fluoroscopic control.
In case of tortuosity the hydrophilic wire was replaced by
a stiff Amplatz wire (Boston Scientific Natick, MA USA). The
selection of the balloon, and/or stent size was based on
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beyond the lesions as a reference (9e12 mm) with a length
appropriate to the lesion (usually 2 or 4 cm). The balloon was
inflated for 10e15 s until satisfactory dilation with abolition
of the ‘waisting’ of the balloon was achieved (6e10 atm).
Stent deployment has been done in 49 cases (63.6%).
Different type of stents were used, depending on the
personal preference of the interventional radiologist.
Balloon expandable stents: nZ 22 Genesis 10  19 mm,
nZ 15 Genesis 10 29 mm, nZ 5 Genesis 9 19 mm, nZ 2
Genesis 8 15 mm, nZ 1 Genesis 8 18 mm, nZ 1 Genesis
9  29 mm (Cordis Corporation, Miami Lakes, FL, USA). Self
expandable stents: n Z 1 S.M.A.R.T 10  25 mm (Cordis
Corporation, Miami Lakes, FL, USA), nZ 1 BARD 12 20 mm
(Murray Hill, NJ, USA), nZ 1 Carotid Wallstent 10  24 mm
(Boston Scientific, Natic, MA, USA) stents were deployed. For
angioplasty, Wanda and Pheron balloons were used: Wanda
9  40 mm, in 46 (59.7%) cases, Wanda 10  40 mm, in 22
(28.6%) cases, Wanda 8  40 mm, in seven (9.1%) cases,
Pheron 8  40 mm (BIOTRONIK GmbH, Berlin, Germany) in
one (1.3%) andPheron740 mminone (1.3%) case. In caseof
stent deployment, Vista Brite Tip (7F) guiding sheath was
utilized. In five patients (5.6%) the re-canalisation of the
stenotic lesion could not be done via femoral access. In these
cases, 4- or 5-F sheaths (Advanti Plus) were used to gain
additional access through the right brachial artery. Following
successful re-canalisation, stent employment was per-
formed through the same access site using 6- or 7-F sheaths.
There were no puncture site occlusion in any of these cases.
A control post-angioplasty angiogramwas performed in each
case (Figs. 1 and 2). No neuroprotection device was utilized
during procedures. Angioplasty was regarded as initially
technically successful, when a residual diameter stenosis
remained of less than 30%. In cases of upper arm claudication
or dizziness, clinical success was defined as relief or
substantial reduction of the preprocedural symptoms.
Aspirin (125 mg daily) was continued (provided there
was no contraindication) for at least 6 months after PTA.
Sixteen (20.8%) patients were treated with dual anti-
platelet therapy, depending the individual decision of the
radiologist. Patients were usually discharged 1 day after the
procedure.
Postoperative clinical evaluation and follow-up exami-
nation was carried out 6 weeks, 3 months and 6 months
after PTA, and annually thereafter. Besides regular
controls, patients were advised to come immediately to our
clinic if they had any acute symptoms. Clinical examination
included pulse palpation; blood pressure measurements on
both arms; subclavian, common carotid and vertebral
artery CDS on both sides and completion of a check list
containing routine questions regarding residual or new
symptoms and co-morbidities.
During the follow-up examinations, the innominate
artery was considered to be patent without significant
stenosis if the right radial pulse was palpable, the blood
pressure difference between the two arms was 30 mmHg or
less and the flow in the vertebral artery was antegrade.
Restenosis was defined as higher than 30 mm Hg difference
in blood pressure between the two arms, recurrent symp-
toms, retrograde flow in the right vertebral artery and/or
more than 50% lumen reduction of the treated vessel at
follow-up.For statistical analysis, the KaplaneMeier method was
employed to calculate cumulative primary and secondary
patency rates (SPSS, version 13.0, Chicago, IL, USA).
This retrospective study has been done according to the
institutional ethical guidelines.
Results
All the lesions but 5 (6.5%) were crossed with balloon
catheter and treated successfully with PTA. All five
attempts failed in cases of occluded innominate artery
(nZ 7) that could not be crossed using either a femoral or
brachial approach. Twenty-eight (36.4%) successful balloon
angioplasties, and 49 (63.6%) PTAs with stent deployment
were carried out. The initial technical success rate was
93.5% for procedures. Examples of successful innominate
artery PTAs without and with stent deployment are shown
in Figs. 1 and 2, respectively In six (7.8%) cases, after stent
deployment, control DSA showed unsatisfactory
morphology and/or higher than 50% residual stenosis. This
was eliminated with repeated PTA. Other supra-aortic PTAs
in the same session with the innominate artery intervention
were carried out in 13 (16.9%) cases.
Clinical primary success was achieved in all but one of
the 58 symptomatic cases, resulting a 98.3% clinical success
rate: 32 patients have become symptomless and 25 patients
showed moderate reductions of the preprocedural symp-
toms. None of the nineteen asymptomatic patients became
symptomatic during or after the procedure within 48 h.
There was neither lethal nor major neurologic compli-
cation nor myocardial infarction during the procedures or
within 30 days of the intervention. Dissection of aortic
arch, or supra-aortic arteries was not observed. There were
two (2.6%) minor neurologic complications: one left-sided
transient hemiparesis occurred during the procedure and
one patient lost consciousness for a short period of time 2 h
following the procedure. Access site complications included
four (5.2%) access site bleedings, resulting in a groin
hematoma, one (1.3%) of them required surgical evaluation
an suture. In one (1.3%) case, palmar and finger pain was
experienced, suggesting transient microemboli.
All but the seven patients with complications were dis-
charged the following day.
The mean follow-up time was 42.3 months (range 2e103
months). Clinical follow-up including both measured data
(blood pressure on both upper extremities, CDS of CCA with
peak sytolic velocity (PSV), end diastolic velocity (EDV) and
systolic rise time (SRT) measurements) and patient history
data (progression of the symptoms, new symptoms and data
on actual medication) is available for 65/72 (90.3%) of all
patients and 68/77 (88.3%) of all procedures. All but five
(6.5%) patients, who were available for follow-up, had
bilateral satisfactory radial pulse, and anterograde flow was
visualised in the right vertebral artery. The difference
between the arms decreased to less than 10 mmHg in all
but 10 (13.9%) patients. In these patients the blood pressure
difference was>30 mmHg, and nine (11.7%) of them showed
relevant symptoms, fulfilling the inclusion criteria for control
angiography. Significant restenosis were identified in four
(5.2%) cases and re-occlusion in one case (1.3%). Successful
re-PTA was done in all five cases, in one patient with stent
deployment. Further follow-up showed open innominate
Figure 1 a and b. Successful PTA (Wanda 9  40 mmWanda, Boston Scientific, Natick, MA) of the innominate artery of a 75-year-
old male patient with hemisymptoms and claudication of the right-upper limb. The patients claudication improved throughout the
follow-up period. The last follow-up duplex scan at 14 months suggested patent innominate artery.
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were analyzed with the KaplaneMeier method; initial tech-
nical failurewas included Fig. 3. Cumulative primary patency
was 100% at 12 months, 98 1.6% at 24 months, and
69.9 8.5%at 96months.Numberof patients at riskwas 56at
12 months, 47 patients at 24 and one patient at 96 months.
The cumulative secondary patency was 100% at 12 and 24
months, and 81.5 7.7% at 96months. Number of patients at
risk calculated for secondarypatencywas 56at 12months, 47
patients at 24 and one patient at 96 months. Log-rank test
showed no significant difference (pZ 0.79) in primary
cumulative patencies between PTA alone and PTA/stent. Six
patients died during follow-up in non-procedure-related
diseases; three deaths caused by gastrointestinal malignant
tumour 14, 17 and 21 months postprocedural, one patient
died of myocardial infarct 3 months postprocedural and one
patient in septic shock 27 months after intervention.
Discussion
Innominate artery lesions are uncommon. They represent
0.5e2% of all vascular lesions (Table 2). Before the era of
endovascular therapy, surgical treatment was the only
option in the management of occlusive disease of innomi-
nate artery. However, it represented only 1.7% of all supra-
aortic operations.10 Lesions of the innominate artery have
been treated via transthoracic or extrathoracic surgicalroute. Mortality of the transthoracic group varies between
3% and 16%; extrathoracic surgical procedures have an
associated lower mortality (0e10%), but have a high
(15e25%) complication rate,2e6 therefore, in recent prac-
tice, surgery is indicated only in the case of unsuccessful
PTA.2,11e13 PTA/stenting of innominate artery has become
the treatment of choice over direct surgical intervention
owing to its lower complication and mortality rates and
shorter hospital stay13 (Table 1). There are only two other
studies on solely innominate artery intervention (Table 2).
In these studies the paraprocedural neurological compli-
cations rate represented 4% TIA, reported by vanHattum et
al., and 2% left occipital infarction beside 6% TIA in our
previous study.14 Primary success rates were 83.3% and
96.4%, respectively.14,15
In contrast to the male predominance in other athero-
matous lesions in other supra-aortic stenoses, innominate
vessel stenoses and occlusions occur with equal frequency
in both sexes, and usually develop after the age of 60.16e18
Our patient group reflected similar gender and age
proportion (Table 1).
Atherosclerosis remains among the leading causes of the
supra-aortic lesions, less common causes may consist of
aortoarteritis (Table 2). The aetiology of the lesions was
atherosclerotic in all cases except one. The youngest
patient had steroid-treated autoimmune aortoarteritis
(Takayasu’s disease) in her previous medical history. This
Figure 2 a and b. Successful PTA and stent (10  19 mm Genesis, Cordis Corp, Miami, Fla) deployment in the innominate artery of
a 67-year-old symptomatic female patient with upper limb claudication. Follow-up duplex scan suggested no restenosis after 57
months follow-up. a, Angiography revealed subocclusion of the innominate artery. b, Control angiography after stent implantation.
Figure 3 KaplaneMeier analysis of cumulative patency rate
for 77 innominate artery interventions, including excluding
initial failures. Since the non-invasive direct visualisation of
the innominate arteries by color duplex scan was not always
possible during follow-up, we refer to “patency rate” rather
than “restenosis-free patency rate” in our analysis.
Innominate Artery PTA 39patient was treated in a non-acute stage of her disease.
Hypertension, diabetes mellitus and smoking are the most
important risk factors for these patients.14,16e18 Our series
reflect similar proportion: 65.3% of all patients suffered
from hypertension, 18.6% had diabetes mellitus and 45.8%
of our patients were smokers.
The indication of angioplasty of innominate vessel is not
well established. There are no data at all on the natural
history. Previous papers evaluate a small number of
innominate artery stenoses, with various inclusion criteria
for PTA (Table 2). Indications for endovascular treatment
are as follows:10,13,19e22 neurologic symptoms (frequency
5e90%), upper limb claudication or digital embolisation,
asymptomatic patients with multivessel disease with or
without subclavian steal syndrome. Due to the above-
mentioned advantages of PTA compared to surgery, at our
clinic all innominate artery stenoses, occlusions are
currently treated with PTA/stenting. Surgery is restricted
to cases of failed endovascular treatment.
In the largest series of innominate artery endovascular
treatment, femoral artery access was gained; the axillary
artery and brachial artery were used less frequently for
access. The latter was associated with higher access site
complication rate.13,14,23In our series, in seven cases of
brachial approach 4 and 5-F-sized sheaths were used No
access site bleeding, nor distal hand/digital embolisation
occurred.
Table 2 Endovascular treatment of innominate artery lesions in the literature over the past 16 years.
Author Year Trial Type No. of
Interventions
No. of Stent
Deployment/
All
Procedures
Indication(s) Primary
success
rate (%)
30 Days
Neurological
Mortality/
Morbidity
Primary
Patency
Rate (% at
months)
Follow-up
time
(months)
Innominate Artery Only
vanHattum, E S et
al.15
2007 Retrospective n Z 25
Innominate
stenoses, nZ 5
Innominate
occlusions
20/30 Multivessel disease,
with risk of cerebral
hypoperfusion
and/or subclavian
steal syndrome (26%),
right arm claudication
83.30 total:
(60 occlusions,
88 stenoses)
4.00% TIA
(amaurosis during
procedure)
79% at 24: 83%
with stent, 67%
without stent
mean 24
Hu¨ttl, K et al.14 2002 Retrospective nZ 89 Innominate 1/89 Symptomatic (upper
limb claudication,
TIA, vertebrobasilar
insufficiency)
96.40 2% left occipital
infarction, 6% TIA
93% at 117 range
12e117
Current Study 2009 Retrospective nZ 77 Innominate 49/77 Symptomatic (upper
limb claudication,
dizziness),
asymptomatic in 24%
of cases
93.5 2.6% TIA 86.1% at 103 mean
42.30
Supraaortic, including Innominate Artery
Mu¨ller-Hu¨lsbeck, S
et al.25
2007 Prospective n Z 8 Innominate,
nZ 36 Subclavian,
n Z 6 CCA, nZ 5
Axillary
22/55 >70% stenosis and/or
symptomatic
stenosis, older than
18 years
100.00 e 90.6% at 20 mean
22.00
Zaytsev, A Y et al.26 2006 Prospective n Z 2 Innominate,
nZ 17 Subclavian,
nZ 2 Vertebral
21/21 Patients with
Vertebrobasilar
insufficiency
96.00 e 100% at 6 mean 21.3
Peterson, B G et al.27 2006 Retrospective n Z 8 Innominate,
n Z 3 Subclavian,
nZ 9 CCA
20/20 80% symptomatic
(stroke, TIA, digital
ischemia/angina, 20%
asymptomatic (90%
stenosis)
100.00 e 100% at 1 1.00
Przewlocki, T et al.28 2006 Prospective n Z 2 Innominate,
nZ 72 Subclavian,
nZ 1 left
Subclavian and
Brachial
66/76 Symptomatic,
significant stenoses or
occlusion
93.40 e 88.5% at 12,
83.6% at 24,
77.2% at 60
mean
24.40
Nagata, S-i et al.29 2005 Case Report nZ 1
Innominate
1/1 Kissing
Stent
Left hemiparesis and
hemisymptoms and
dysarthria
100.00 e 100% at 3 3.00
Modarai, B et al.1 2004 Prospecive n Z 1 Innominate,
nZ 40 Subclavian
unknown Symptomatic 85.37 e 82% at 48 mean
48.00
40
T.M
.
P
a
u
ko
vits
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l.
Gonza´les, A et al.30 2002 Prospective n Z 2 Innominate,
nZ 7 Subclavian
8/9 Symptomatic
occlusions
100.00 e 77.8% at 40 mean
37.40
Azzarone, M et al. 2000 Case Report nZ 1 Innominate 1/1 Symptomatic
(amaurosis fugax)
subtotal occlusion
100.00 e 100% at 12 12
Ko¨rner, J et al.31 1999 Prospective n Z 4 Innominate,
nZ 38 Subclavian,
nZ 1 Subclaviane
Subclavian
bypass
0/43 Symptomatic
(subclavian steal sy,
upper extremity
arterial insufficiency,
peripheral
thromboembolism,
PRIND/stroke)
84.00 9% cerebrovascular
thromboembolism
72% at 100 mean 15
Sullivan, T M et al.12 1998 Prospective n Z 7 Innominate,
nZ 66 Subclavian,
nZ 14 CCA
87/87 Symptomatic 94.30 2.3% ischemic
stroke in CCA
interventions
85% at 35 mean 14.3
Motarjeme, A et al.32 1993 Prospective n Z 9 Innominate,
nZ 66 Subclavian,
n Z 3 Axillary,
n Z 3 Brachial,
n Z 35 Vertebral,
n Z 6 CCA, n Z 7
ICA, nZ 2 ECA
0/131 Symptomatic 93.00 total,
(98 for stenotic
lesions, vs. 40
for total
occlusions)
0.76% TIA
(temporary
bilateral blindness)
96.3% at 60 mean 60
Selby J B et al.33 1992 Prospecive n Z 2 Innominate,
nZ 26 Subclavian,
nZ 4 Axillary
0/32 Arm Claudication,
Vertebrobasilar
Insufficiency, Graft
Dilatation
100.00 e 96.9% at 90 mean
36.00
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42 T.M. Paukovits et al.Our series reflects similarly excellent primary success
rate as the relevant literature (Table 2). In conclusion, high
occlusions/stenoses rate results poor primary outcome. The
use of new, lower profile balloons and stents might obviate
this problem.
The principal advantage of stent placement in the
treatment of innominate artery stenoses is its impact on
the immediate outcome. However, there is no evidence
that stenting is superior to angioplasty alone for innominate
artery lesions; current practice includes primary stenting
when highly calcified lesions are present and stenting
lesions with significant residual stenosis after balloon
angioplasty. Only one stent was depleted during 89 inter-
ventions in the largest retrospective study on the topic,
carried out at our institution between 1989 and 2000.14
Compared to the present study, in which 49/77 (63.6%)
stents were used, primary and secondary patency rates are
highly similar. However, the comparison of the two patient
groups is limited, because of inhomogeneous patient pop-
ulations, regarding availability of stents and varying indi-
cations for stent deployment in the two studies.
Due to the anatomic position of the treated lesions, the
non-invasive, direct visualisation of innominate vessel is
mostly not possible; thus, we cannot exclude the chance of
a restenosis in symptomless patients in whom no angiog-
raphy was performed. We refer to open, patent innominate
artery in all the asymptomatic patients with a present
radial pulse and blood pressure difference less than 30
mmHg between the two arms. Asymptomatic restenoses
might therefore be missed and the patency rate may be
lower than reported. Literature on solely innominate artery
intervention describes 79e93% primary patency at 24 and
117 months, respectively (Table 2).
During our study, no periprocedural neuroprotection
device was used. The previous relevant cohort studies do
not report the use of neuroprotection devices during the
treatment of innominate artery either.24e33 According to
the largest series on transluminar endovascular treatment
of proximal common carotid artery (pACC), in which no
neuroprotection was used, the use of neuroprotection
devices would be technically difficult in innominate artery
as well, without an established indication.34 Dual anti-
platelet therapy was not routinely used in many of the
published studies of innominate artery endovascular
procedures, including this report. However, use of dual
anti-platelet therapy may further reduce the number of
neurological complications associated with innominate
endovascular treatment.
The main limitation of this study is its retrospective
nature. In addition, due to the long period studied
(2000e09), the population was not homogeneous as to
whether or not stents, and/or dual anti-platelet
therapy were used. For the same reason, follow-up is
missing for 9.7% of the procedures; however, procedural
and in-hospital clinical outcomes were available for all
77 treatments. The number of restenoses, especially
those below 70%, may also be underestimated due to
the limitations of duplex scan examination in visual-
isation of innominate artery. The lack of significant
differences of patency rate between angioplasty alone
and angioplasty stenting may also be due to the rela-
tively small sample size.In conclusion, this is one of the three studies published
on angioplasty/stenting of solely the innominate artery.
The primary technical success rate is high (93.5%) with a 0%
30-day all stroke/death rate. Our results should help
vascular surgeons and interventional radiologists to
consider risk versus benefit when deciding treatment
options for innominate artery lesions.
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